Risk of nephrogenic systemic fibrosis (NSF) in oncology patients receiving gadoxetic acid and updated risk of estimate of NSF in patients receiving gadoxetic acid with moderate and severe renal impairment.
Gauthier ID, Macleod CA, Sathiadoss P, McGrath TA, Nair V, Schieda N.
The Fibrosis and Immunological Features of Hypochlorous Acid Induced Mouse Model of Systemic Sclerosis.
Meng M, Tan J, Chen W, Du Q, Xie B, Wang N, Zhu H, Wang K.
Front Immunol. 2019 Aug 20;10:1861. doi: 10.3389/fimmu.2019.01861. eCollection 2019.
PMID:31481954
Nephrogenic systemic fibrosis.
Kaewlai R, Abujudeh H.
AJR Am J Roentgenol. 2012 Jul;199(1):W17-23. doi: 10.2214/AJR.11.8144.
PMID:22733927
Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction.
Kay J.
Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii66-9. doi: 10.1136/ard.2008.102475.
PMID:19022818
Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration.
Kanal E, Patton TJ, Krefting I, Wang C.
AJNR Am J Neuroradiol. 2020 Mar;41(3):393-399. doi: 10.3174/ajnr.A6448. Epub 2020 Feb 27.
PMID:32115422
Nephrogenic Systemic Fibrosis in the Setting of Transient Renal Insufficiency.